|
POTENTIAL FOR RARE LIFE-THERATENING HEPATIC VENO-OCCLUSIVE DISEASE
|
CYCLOPHOSPHAMIDE PRETREATMENT IN THE PATIENT MAY REDUCE THE TOXICITY OF MELPHALAN
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
INCREASED POTENTIAL FOR HEPATOTOXICITY
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
IMMUNOSUPPRESSANT DRUGS CONCOMITANT USE MAY INCREASE CHANCES OF DEVELOPING MYOPATHY
|
CHLORAMPHENICOL MAY REDUCE THE METABOLISM OF CYCLOPHOSPHAMIDE TO ITS ACTIVE FORM
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
HYPOGLYCEMIC EFFECT MAY INCREASE OR DECREASE
|
ADDITIVE MYELOSUPPRESSION WHEN USED WITH OTHER MYELOSUPPRESSIVE DRUGS
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
CO-ADMINISTRATION WITH HMG-COA REDUCTASE INHIBITORS THAT ARE METABOLIZED BY CYP3A PATHWAY, SUCH AS ATORVASTATIN, INCREASE THE RISK OF MYOPATHY & RHABDOMYOLYSIS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
CYCLOPHOSPHAMIDE MAY BOTH INCREASE OR DECREASE THE BLOOD SUGAR LEVELS
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|
VACCINES HAVE POOR RESULT IF GIVEN DURING THE DRUG THERAPY
|